Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients

摘要: Oral mucositis (OM) is among the most undesirable, painful, and expensive toxicities of cytotoxic cancer therapy, disheartening for patients frustrating caregivers. Accurate assessment incidence OM has been elusive, but accumulating data suggests that reported frequency significantly less than its actual occurrence. It suggested over 90% head neck (HNC) receiving radiotherapy (RT) with concurrent cisplatin experience severe symptoms extreme pain, mucosal ulceration consequent limitations in swallowing achieving adequate nutritional intake. This panoply inevitably impacts a patients’ quality life their willingness to continue treatment. In spite all advances made understanding pathophysiology OM, there still no prophylactic therapy proven efficacy. Strategies limit extent manage symptomatology include basic oral care, supportive medications, support targeting aggressive treatments high-risk patients. review focuses on recognition, preventive measurements, symptom-management strategies.